Latest Funding News

Region Group reports a robust first half of FY25 with $81.8 million net profit and an 8% growth in assets under management, underpinned by stable occupancy and strategic capital recycling.

Region Group has reported a remarkable turnaround with an $81.8 million net profit for the half year ended December 2024, reversing last year's loss while maintaining its interim distribution at 6.70 cents per security.

Macquarie Group's 3Q25 trading update reveals strong growth in annuity-style businesses offset by a significant decline in markets-facing segments due to subdued commodity markets. The group's capital position remains robust, comfortably exceeding regulatory requirements.

Vulcan Steel Limited reported a challenging first half of FY25 with significant declines in revenue, EBITDA, and net profit, yet maintained a solid 10% return on capital employed and declared a cautious interim dividend.

Foresta Group Holdings has signed a non-binding term sheet with Genesis Energy to supply torrefied wood pellets for Huntly Power Station, marking a pivotal step toward reducing New Zealand’s coal dependency by 2028.

Pro-Pac Packaging has updated its quarterly cash flow report, highlighting a net cash outflow from operations and outlining plans to improve margins and secure longer-term funding.

Lodestar Minerals has increased its capital raising placement by $22,500, bringing the total to $542,500, subject to shareholder approval at an upcoming meeting.

JPMorgan Asset Management has announced estimated cash distributions for its Global Equity Premium Income ETFs for February 2025, alongside a detailed timetable for investors to follow.

Yowie Group Ltd has called in its loan facility with Keybridge Capital Limited following Keybridge's appointment of a Voluntary Administrator, prompting Yowie to explore new capital solutions amid recovery uncertainties.

Sarytogan Graphite Limited has received A$2.36 million from the EBRD as part of a second tranche equity investment, boosting the bank’s stake to 17.3%. An independent peer review affirms the project’s promise while highlighting manageable risks.

Alterity Therapeutics has raised A$40 million through a two-tranche placement to advance its lead compound ATH434 for neurodegenerative diseases, including Multiple System Atrophy and Parkinson's disease.

Inventis Limited updates its operational review with corrected financials, securing major orders and pursuing significant capital raises to fuel international expansion.